Candida auris is a highly drug-resistant, hospital-acquired fungal pathogen. With limited treatment options, here is an overview of some of the next-generation antifungals as well as combination therapeutics.
Tina Zheng, PharmD, BCIDP
Advertisement
Zheng, PharmD, BCIDP, is an infectious diseases clinical pharmacist at Maimonides Medical Center.
(https://orcid.org/0009-0005-6107-4657)
Articles by Tina Zheng, PharmD, BCIDP
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Contagion Live
1
US Completely Revamps Childhood Vaccine Schedule to Resemble Small European Country
2
Unlocking New Defenses: The Changing Landscape of Candida auris Management
3
What's New in 2025: From the CLSI Subcommittee on Antimicrobial Susceptibility Testing
4
Training Healthcare Professionals to Treat High-Consequence Infectious Disease
5